Inovio spinout plans pivotal study for cancer vaccine as it touts alternative take on PhIb/IIa liver cancer data

In­ovio spin­out Ge­neos Ther­a­peu­tics said Tues­day that it has three new par­tial re­spons­es and one case of sta­ble dis­ease from a mid-stage liv­er can­cer tri­al test­ing its per­son­al­ized can­cer vac­cine can­di­date in com­bi­na­tion with Mer­ck’s Keytru­da. How­ev­er, the biotech is claim­ing these re­spons­es as “com­plete mol­e­c­u­lar re­spons­es.”

Ge­neos re­port­ed the four “com­plete mol­e­c­u­lar re­spons­es” Tues­day morn­ing, tout­ing an analy­sis of the pa­tient’s cir­cu­lat­ing tu­mor DNA, or ctD­NA. That met­ric of­fers a dif­fer­ent pic­ture from RE­CIST1.1, which Ge­neos CEO Ni­ran­jan Sarde­sai ac­knowl­edged is the gold stan­dard for de­ter­min­ing ob­jec­tive re­spons­es, or changes in tu­mor size.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.